Under the supervision of the Dean of the College of Pharmacy, Professor Dr. Sarmed H. Kathem Alkhateeb, the Scientific Affairs Unit at the University of Baghdad/College of Pharmacy, held an in-person workshop entitled “Rezdiffra: the first drug FDA approved for non-alcoholic steatohepatitis delivered by pharmacist Noor Mubder khalf, a master student at the clinical pharmacy Department.The workshop aimed to introduce this recently approved medication by food and drug administration for treating adults with nonalcoholic-steatohepatitis with moderate to advanced liver fibrosis, without cirrhosis .It represents a promising option for improving liver function and reducing fibrosis progression.The workshop included an introduction to the disease, causes, progression and an explanation of the preliminary and clinical studies conducted on the drug before its approval. Dosage form, doses, interactions with other medications, and side effects were also discussed. The mechanism of action of this drug is a selective thyroid hormone-beta agonist that reducing hepatic fat accumulation, Lowers liver inflammation and fibrosis and improves lipid metabolism.The workshop concluded that this drug has successfully treated 80% of cases. Demonstrated that significant reduction in liver inflammation and fibrosis markers, decreased intrahepatic fat levels as assessed by magnetic resonance imaging (MRI) and generally well-tolerated safety profile. It should be taken alongside a healthy lifestyle, including diet and exercise.
